| III-80 Hanna Silber Baumann Dose confirmation based on population pharmacokinetics within LUMINESCE (NCT04963270); a Phase III, randomized, double-blind, placebo-controlled study evaluating satralizumab in patients with generalized myasthenia gravis Thursday 10:15-11:45 |
